What is B. Riley’s Forecast for VKTX Q4 Earnings?

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at B. Riley issued their Q4 2024 EPS estimates for Viking Therapeutics in a report released on Thursday, November 21st. B. Riley analyst M. Mamtani expects that the biotechnology company will post earnings of ($0.24) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.98) per share. B. Riley also issued estimates for Viking Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.23) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($1.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.02. During the same quarter in the previous year, the company earned ($0.23) earnings per share.

Several other analysts have also recently commented on VKTX. HC Wainwright restated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Tuesday. Oppenheimer reissued an “outperform” rating and set a $138.00 price objective on shares of Viking Therapeutics in a report on Wednesday, September 25th. William Blair reiterated an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. JPMorgan Chase & Co. initiated coverage on Viking Therapeutics in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $105.00 price objective on shares of Viking Therapeutics in a research report on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Buy” and an average target price of $109.73.

Viking Therapeutics Trading Up 2.8 %

Shares of VKTX stock opened at $53.42 on Monday. Viking Therapeutics has a 1-year low of $11.55 and a 1-year high of $99.41. The stock’s fifty day simple moving average is $63.43 and its 200-day simple moving average is $60.05. The company has a market capitalization of $5.95 billion, a price-to-earnings ratio of -57.44 and a beta of 1.00.

Institutional Investors Weigh In On Viking Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC increased its stake in Viking Therapeutics by 10,775.6% in the third quarter. International Assets Investment Management LLC now owns 1,004,033 shares of the biotechnology company’s stock valued at $63,565,000 after purchasing an additional 994,801 shares in the last quarter. Perpetual Ltd grew its stake in Viking Therapeutics by 55.4% in the third quarter. Perpetual Ltd now owns 1,269,152 shares of the biotechnology company’s stock valued at $80,350,000 after acquiring an additional 452,344 shares during the period. Fiera Capital Corp bought a new position in shares of Viking Therapeutics during the 3rd quarter valued at about $18,443,000. Artal Group S.A. acquired a new position in shares of Viking Therapeutics in the 1st quarter valued at approximately $20,817,000. Finally, Eventide Asset Management LLC increased its stake in Viking Therapeutics by 79.1% during the 3rd quarter. Eventide Asset Management LLC now owns 452,969 shares of the biotechnology company’s stock worth $28,677,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors own 76.03% of the company’s stock.

Insider Activity at Viking Therapeutics

In related news, CEO Brian Lian sold 216,130 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $70.83, for a total value of $15,308,487.90. Following the completion of the transaction, the chief executive officer now owns 2,304,927 shares in the company, valued at $163,257,979.41. The trade was a 8.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director J Matthew Singleton sold 10,300 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $69.50, for a total value of $715,850.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at $660,250. This trade represents a 52.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 371,117 shares of company stock valued at $27,140,009 in the last ninety days. Insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.